Combination oral contraceptive pills offer BMI, lipid benefit in PCOS

  • Li L & al.
  • BMC Womens Health
  • 27/02/2020

  • Elisabeth Aron, MD, MPH, FACOG
  • Clinical Essentials
L'accesso ai contenuti di questo sito è riservato agli operatori del settore sanitario italiano L'accesso ai contenuti di questo sito è riservato agli operatori del settore sanitario italiano

Takeaway

  • The combination of 3 mg drospirenone (DRSP) and 20 μg ethinyl estradiol (EE) has favorable metabolic and hormonal effects in people with PCOS.

Why this matters

  • DRSP has antimineralocorticoid and antiandrogenic activities.
  • The prevalence of PCOS among reproductive-age women is 6%-10%.

Key results

  • Improvements in metabolic and hormonal profile after 3 months of DRSP/EE tablets:
    • Decreased BMI (P<.001 waist-hip ratio>
    • Decreased testosterone (P<.001>
    • Increased high-density lipoprotein-cholesterol (P<.001>
    • Decreased ovarian volume (P<.05>
  • No change in blood glucose levels or insulin resistance.
  • 42.14% of patients reported discomfort including gastrointestinal disorder, dizziness, headache, breast swelling, or irregular bleeding.

Study design

  • Single-center, prospective, observational study.
  • Patients with PCOS were prescribed once daily DRSP/EE tablets (n=140).
  • Anthropometric measurements, sex hormones, glucolipid metabolic index, ovarian volume, and adverse effects were recorded at baseline and after 3 months of treatment.
  • Funding: Science and Technology Planning Project of Guangdong Province; Key Project of Guangdong Provincial Administration of Traditional Chinese Medicine; Guangzhou Municipal Science and Technology Innovation Council.

Limitations

  • Small sample size.
  • Retrospective study.
  • Single center, so results may not be generalizable.